Nasa Takahashi

[Achievement : Evaluation and Prioritization of Drug Candidates] - Comprehensive Literature / database evaluation and build up the shortlist to strengthen company pipeline: By conducting thorough searches of the latest research and Sales forecasting, 20 innovative drug candidates that address unmet medical needs are identified and evaluated 2000 Oku-yen for the potential in Japan market.

[Achievement] - Pipeline Strengthening and acquiring high revenue products : Proceed DD Novel 3 Drugs: Evaluating and Triage the rights to new drugs in clinical development to bolster the product pipeline and secure future revenue streams for Rare disease business unit in 3 disease area with global stakeholders.

[Achievement] - Successfully Launched New Project: Spearheaded the launch of a new business as disease awareness and diagnosis, engaging stakeholders from executive leadership with ADS member's, Market access, and marketing / sales to develop a comprehensive project. - Achieved target KPI to make the strategy to achieve diagnosis rate within the first year, creating a new digital/remote scheme for the company for HAE/VWD/Fabry/CIDP/PID. - Managed 9 peoples and successfully make the phycological safety environment, and self-motivated organization.

[Repositioned Legacy Brand] - Led a digital re-branding campaign focused on patient centricity marketing to reposition an established VPR brand for a doctors. Successfully patient centricity marketing using innovative skills and significantly contributed to new patient prescription.

[Achievements] - Lead the Nexviazyme launch, and make strategy under the COVID-19 situation to built Seamless Omnichannel scheme, Constructed an omnichannel strategy that seamlessly integrated online and offline customer experiences for Pompe disease. By leveraging customer data analytics to deliver personalized marketing campaigns through Digital channel and MR channel, we maximized the value of Nexviazyme and overturned Myozyme patient treatment numbers trend. Our Japan Pompe team gain the 2 global award (1st prize and 2nd prize) with it.